🇪🇺 Comtess® in European Union

EMA authorised Comtess® on 16 September 1998

Marketing authorisation

EMA — authorised 16 September 1998

  • Application: EMEA/H/C/000170
  • Marketing authorisation holder: Orion Corporation
  • Local brand name: Comtess
  • Indication: Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
  • Status: approved

Read official source →

Other Neurology approved in European Union

Frequently asked questions

Is Comtess® approved in European Union?

Yes. EMA authorised it on 16 September 1998.

Who is the marketing authorisation holder for Comtess® in European Union?

Orion Corporation holds the EU marketing authorisation.